Skip to main content

Animations

MJFF Publications

6751 - 6760 of 8816 Results
Title
Year
  • Year
  • 2017
  • 2017
  • 2020
  • 2022
  • 2023
  • 2011
  • 2013
  • 2023
  • 2025
  • 2018
  • Summary Details
    OPEN
    Title: S-Nitrosylation of PINK1 Attenuates PINK1/Parkin-Dependent Mitophagy in hiPSC-Based Parkinson’s Disease Models
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2017.10.068
    Citation Count: 113
  • Summary Details
    OPEN
    Title: Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20170803
    Citation Count: 160
  • Summary Details
    OPEN
    Title: Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2020.105134
    Citation Count: 31
  • Summary Details
    OPEN
    Title: The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/mds.29133
    Citation Count: 8
  • Summary Details
    RESTRICTED
    Title: A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105325
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(11)70175-2
    Citation Count: 325
  • Summary Details
    OPEN
    Title: Phosphoproteomic evaluation of pharmacological inhibition of leucine‐rich repeat kinase 2 reveals significant off‐target effects of LRRK‐2‐IN‐1
    Journal Name: Journal of Neurochemistry
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/jnc.12483
    Citation Count: 63
  • Summary Details
    OPEN
    Title: Effects of Parkin on the Mitochondrial Genome in the Heart and Brain of Mitochondrial Mutator Mice
    Journal Name: Advanced Biology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/adbi.202300154
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Cache: Utilizing ultra-large library screening in Rosetta to identify novel binders of the WD-repeat domain of Leucine-Rich Repeat Kinase 2
    Journal Name: Journal of Cheminformatics
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13321-025-01084-3
    Citation Count: 0
  • Summary Details
    OPEN
    Title: TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
    Journal Name: Journal of Experimental Medicine
    Publisher: Rockefeller University Press
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-sa
    DOI - Digital Object Identifier: 10.1084/jem.20180484
    Citation Count: 66
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.